Advances in the treatment and genetics and translational research of patients with Mantle cell lymphoma.
10.3760/cma.j.cn511374-20250826-00513
- Author:
Shuhua YI
1
;
Lugui QIU
Author Information
1. Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China. qiulg@ihcams.ac.cn.
- Publication Type:English Abstract
- MeSH:
Humans;
Lymphoma, Mantle-Cell/immunology*;
Translational Research, Biomedical;
Hematopoietic Stem Cell Transplantation;
Immunotherapy
- From:
Chinese Journal of Medical Genetics
2025;42(12):1409-1414
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma (MCL) is a rare B-cell lymphoma characterized by both the incurable nature of indolent lymphomas and the clinical course of aggressive lymphomas. The integration of high-dose cytosine arabinoside (Ara-C) and autologous hematopoietic stem cell transplantation (ASCT) has led to substantial improvement in the outcomes of MCL patients in the immunochemotherapy era. More recently, the widespread use of small molecule targeted agents, particularly Bruton tyrosine kinase inhibitor (BTKi), has re-shaped the therapeutic landscape of MCL patients and challenged the traditional role of high-dose Ara-C and ASCT. Novel immunotherapies including bi-specific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy have emerged as important treatment options for MCL patients with relapsed or refractory disease. With advances in multi-omics profiling, the development of personalized, potentially curative strategies based on individual genetic and immune features is expected to become a major focus of future research on MCL. This article will delve into the latest research progress in the treatment and genetics and translational research on MCL patients, focusing on the latest progress of research on the treatment of newly diagnosed MCL patients, treatment of relapsed/refractory MCL patients, and the genetics and translational treatment of MCL patients, and explore the evolution and future direction of its treatment model.
